WO2005034968A1 - Solution for cessation of smoking and method to use - Google Patents

Solution for cessation of smoking and method to use Download PDF

Info

Publication number
WO2005034968A1
WO2005034968A1 PCT/US2003/034971 US0334971W WO2005034968A1 WO 2005034968 A1 WO2005034968 A1 WO 2005034968A1 US 0334971 W US0334971 W US 0334971W WO 2005034968 A1 WO2005034968 A1 WO 2005034968A1
Authority
WO
WIPO (PCT)
Prior art keywords
base solution
water base
therapeutic
approximately
therapeutic water
Prior art date
Application number
PCT/US2003/034971
Other languages
French (fr)
Inventor
Luis Viola
Original Assignee
Sanchelima And Associates, P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanchelima And Associates, P.A. filed Critical Sanchelima And Associates, P.A.
Priority to AU2003286868A priority Critical patent/AU2003286868A1/en
Publication of WO2005034968A1 publication Critical patent/WO2005034968A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to a therapeutic antismoking solution and method for its administration, and more particularly, to a therapeutic solution for rinsing and discarding from the mouth for promoting the cessation of smoking and a method to use.
  • III. BACKGROUND ART For many years now, scientists have analyzed and published the health hazards related to smoking. There are many health risks associated with cigarette smoking including, but not limited to, cancer, lung and respiratory system damage, raising of blood pressure, and decreased circulation of oxygen to the brain and body.
  • Cigarette smoking also is a significant risk factor for emphysema, chronic bronchitis, stroke, high blood pressure, and osteoporosis.
  • many statistics have also been developed comparing nonsmokers to smokers. As compared to a nonsmoker, the average smoker is fourteen times as likely to die of lung cancer, fourteen times as likely to die of mouth or throat cancer, four times as likely to die of cancer of the esophagus, twice as likely to die of a heart attack, and twice as like to die of bladder cancer.
  • smoking is addictive. Specifically, the US Food and Drug Administration findings conclude that smoking is addictive.
  • the instant invention is a therapeutic water base solution for oral administration in humans comprising an effective amount of silver nitrate and glycerine to chemically react with nicotine to produce a repugnant aftertaste. More specifically, the therapeutic water base solution produces the repugnant aftertaste to the humans upon lighting and inhaling a cigarette or smoking device containing the nicotine. This is due to the nicotine content of the cigarette or smoking device chemically reacting with the therapeutic water base solution. The therapeutic water base solution reacts with taste buds of the humans to produce the repugnant aftertaste lasting at least two to six hours.
  • the therapeutic water base solution comprises approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water in a concentrated form.
  • the therapeutic water base solution is diluted to the effective amount.
  • the effective amount comprises a ratio of approximately 65% to 85% water and 15% to 35% concentrated form.
  • Another subject matter of the invention is a method of using a therapeutic water base solution to reduce the desire of a human being to smoke, comprising the steps of: A) diluting a concentrated solution comprising approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water to a ratio of approximately 65% to 85% water and 35% to 15% concentrated solution; B) administering the therapeutic water base solution orally; C) rinsing and/ or gargling the therapeutic water base solution with a dose of approximately 0.06 liter up to three times, up to six times a day, for a period of at least 30 days; and D) expelling the therapeutic water base solution.
  • Yet another subject matter of the invention is a method of preparing a concentrated solution, comprising the steps of: A) obtaining approximately between 170.00 cc and 230.00 cc of demineralized water; B) mixing approximately between 1.70 cc and 2.30 cc of silver nitrate into the demineralized water; and C) mixing approximately between 8.50 cc and 11.50 cc of glycerine into the demineralized water.
  • It is another object of the present invention to provide a method to reduce the desire of a human being to smoke.
  • the present invention decreases the overall desire to smoke. Without being bound by any theory, the present inventor believes that the therapeutic solution when administered, produces a repugnant aftertaste to the user upon lighting and inhaling a cigarette or similar smoking device containing nicotine, due to the nicotine content of the cigarette chemically reacting with the ingredients of the therapeutic solution. Again, without being bound by any theory, the present inventor believes that the therapeutic solution comprising silver nitrate, glycerine, and demineralized water reacts with taste buds of the smoker to produce the repugnant aftertaste to the user lasting at least two to six hours.
  • silver nitrate a chemical compound, AgN0 3 ; a colorless crystalline material that is very soluble in water.
  • the most important compound of silver it is used in the preparation of silver salts for photography, in chemical analysis, in silver plating, in inks and hair dyes, and to silver mirrors. It is used in medicine in the treatment of eye infections and gonorrhea.
  • Fused silver nitrate is also called lunar caustic. Taken internally silver nitrate is a poison. It is prepared by reaction of nitric acid with silver, and purified by recrystallization. It is darkened by sunlight or contact with organic matter such as the skin.
  • glycerine The Columbia Encyclopedia, Sixth Edition, 2001, defines glycerine as: glycerin, glycerine, or 1,2,3-propanetriol, CH 2 OHCHOHCH 2 OH; colorless, odorless, sweet-tasting, syrupy liquid.
  • Glycerol is a trihydric alcohol. It melts at 17.8°C, boils with decomposition at 290°C, and is miscible with water and ethanol. It is hygroscopic; i.e., it absorbs water from the air; this property makes it valuable as a moistener in cosmetics.
  • Glycerol is present in the form of its esters (glycerides) in all animal and vegetable fats and oils.
  • Glycerol is also synthesized on a commercial scale from propylene (obtained by cracking petroleum), since supplies of natural glycerol are inadequate. Glycerol can also be obtained during the fermentation of sugars if sodium bisulfite is added with the yeast. Glycerol is widely used as a solvent; as a sweetener; in the manufacture of dynamite, cosmetics, liquid soaps, candy, liqueurs, inks, and lubricants; to keep fabrics pliable; as a component of antifreeze mixtures; as a source of nutrients for fermentation cultures in the production of antibiotics; and in medicine.
  • the present inventor believes that the repugnant aftertaste to the user produced from the reaction of the therapeutic solution with lighting and inhaling a cigarette or similar smoking device will reduce the desire and addiction of smoking for the user through continuous administration of the therapeutic solution.
  • the concentrated solution the content seen in chart 1
  • the diluted therapeutic solution is then administered with a dose of approximately 0.06 liter, up to six times a day, preferably orally, for a period of 30 days.
  • the administration comprises the user rinsing and /or gargling up to three times with the 0.06 liter of diluted therapeutic solution and expelling it from the mouth of the user.
  • smokers were administered the diluted therapeutic solution and all described a repugnant aftertaste to their taste buds lasting at least two to six hours upon lighting and inhaling a cigarette or similar smoking device containing nicotine.
  • Another subject matter of the invention is a method of using a therapeutic water base solution to reduce the desire of a human being to smoke, comprising the steps of: A) diluting a concentrated solution comprising approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water to a ratio of approximately 65% to 85% water and 15% to 35% said concentrated solution; B) administering said therapeutic water base solution orally; C) rinsing and /or gargling said therapeutic water base solution with a dose of approximately 0.06 liter up to three times, up to six times a day, for a period of at least 30 days; and D) expelling said therapeutic water base solution.
  • the therapeutic water base solution may be administered in aerosol form.
  • Yet another subject matter of the invention is a method of preparing a concentrated solution, comprising the steps of: A) obtaining approximately between 170.00 cc and 230.00 cc of demineralized water; B) mixing approximately between 1.70 cc and 2.30 cc of silver nitrate into said demineralized water; and C) mixing approximately between 8.50 cc and 11.50 cc of glycerine into said demineralized water.
  • chart 1 The specification of an example concentrated solution prepared according to the described method is seen in chart 1 below. The contents listed are an average, and may fluctuate; cc is a metric unit of volume equal to one thousandth of a liter.
  • the concentrated solution is prepared according to the measurements seen in chart 1, however, silver nitrate may measure approximately between 1.70 cc and 2.30 cc; glycerine may measure approximately between 8.50 cc and 11.50 cc; and demineralized water may measure approximately between 170.00 cc and 230.00 cc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A therapeutic water base solution, comprising: silver nitrate, glycerine, and demineralized water. The therapeutic water base solution when administered, produces a repugnant aftertaste to a user upon lighting and inhaling a cigarette or similar smoking device containing nicotine, due to the nicotine content of the cigarette chemically reacting with the ingredients of the therapeutic water base solution. The therapeutic water base solution reacts with taste buds of the smoker to produce the repugnant aftertaste to the user lasting at least two to six hours. A method of using a therapeutic water base solution to reduce the desire of a human being to smoke is also disclosed and in addition, a method of preparing a concentrated solution.

Description

I. TITLE: " SOLUTION FOR CESSATION OF SMOKING AND METHOD TO USE " II. TECHNICAL FIELD The present invention relates to a therapeutic antismoking solution and method for its administration, and more particularly, to a therapeutic solution for rinsing and discarding from the mouth for promoting the cessation of smoking and a method to use. III. BACKGROUND ART For many years now, scientists have analyzed and published the health hazards related to smoking. There are many health risks associated with cigarette smoking including, but not limited to, cancer, lung and respiratory system damage, raising of blood pressure, and decreased circulation of oxygen to the brain and body. Cigarette smoking also is a significant risk factor for emphysema, chronic bronchitis, stroke, high blood pressure, and osteoporosis. Complementing publications regarding the above mentioned, many statistics have also been developed comparing nonsmokers to smokers. As compared to a nonsmoker, the average smoker is fourteen times as likely to die of lung cancer, fourteen times as likely to die of mouth or throat cancer, four times as likely to die of cancer of the esophagus, twice as likely to die of a heart attack, and twice as like to die of bladder cancer. However, in light of all the health hazards scientifically proven to develop from smoking, people still smoke. Scientific studies have concluded that smoking is addictive. Specifically, the US Food and Drug Administration findings conclude that smoking is addictive. In a 1995 report on smoking and addiction, the US Food and Drug Administration concluded that 87% of those who smoke cigarettes smoke every day. Other findings reported included that nearly two-thirds of smokers have their first cigarette within half an hour of waking up, 84.3% of those who smoked 20 or more cigarettes per day had unsuccessfully tried to reduce the number of cigarettes they smoked; a smoker who makes a serious attempt to stop smoking has a less than 5% chance of being off cigarettes a year later; 70% of current smokers said that they would like to stop smoking completely; 83-87% of cigarette smokers who smoke more than 26 cigarettes a day believe they are addicted; almost half the smokers who undergo surgery for lung cancer resume smoking; even after smokers have had their larynxes removed, 40% try smoking again; even among adults who express a strong desire to quit smoking and who receive optimal medical care, only half the patients studied were able to stop smoking for as long as one week, and the long-term failure rate was more than 80% after patients were withdrawn from nicotine replacement; major recent studies conclude that at least 75% and as many as 90% of frequent smokers meet the criteria for addiction established by major public health organizations. Many other health authorities around the world have reported similar findings, and the conclusion is clear: smoking is addictive, and more specifically, smoking is addictive because of the nicotine content in smoking devices such as cigarettes. Anti-smoking campaigns have been developed in an effort to assist smokers to quit and to prevent non-smokers from smoking. Additionally, many aids and/or tactics for smoking cessation have been designed in the past. None of them, however, includes a therapeutic water base solution comprising silver nitrate, glycerine, and demineralized water. There are no similar therapeutic solutions incorporating a method to use to assist smokers to quit to the best of applicant's knowledge that comprises silver nitrate, glycerine, and demineralized water. IV. SUMMARY OF THE INVENTION The instant invention is a therapeutic water base solution for oral administration in humans comprising an effective amount of silver nitrate and glycerine to chemically react with nicotine to produce a repugnant aftertaste. More specifically, the therapeutic water base solution produces the repugnant aftertaste to the humans upon lighting and inhaling a cigarette or smoking device containing the nicotine. This is due to the nicotine content of the cigarette or smoking device chemically reacting with the therapeutic water base solution. The therapeutic water base solution reacts with taste buds of the humans to produce the repugnant aftertaste lasting at least two to six hours. The therapeutic water base solution comprises approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water in a concentrated form. The therapeutic water base solution is diluted to the effective amount. The effective amount comprises a ratio of approximately 65% to 85% water and 15% to 35% concentrated form. Another subject matter of the invention is a method of using a therapeutic water base solution to reduce the desire of a human being to smoke, comprising the steps of: A) diluting a concentrated solution comprising approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water to a ratio of approximately 65% to 85% water and 35% to 15% concentrated solution; B) administering the therapeutic water base solution orally; C) rinsing and/ or gargling the therapeutic water base solution with a dose of approximately 0.06 liter up to three times, up to six times a day, for a period of at least 30 days; and D) expelling the therapeutic water base solution. Yet another subject matter of the invention is a method of preparing a concentrated solution, comprising the steps of: A) obtaining approximately between 170.00 cc and 230.00 cc of demineralized water; B) mixing approximately between 1.70 cc and 2.30 cc of silver nitrate into the demineralized water; and C) mixing approximately between 8.50 cc and 11.50 cc of glycerine into the demineralized water. It is therefore one of the main objects of the present invention to provide a therapeutic water base solution to assist smokers to quit smoking. It is another object of the present invention to provide a method to reduce the desire of a human being to smoke. It is yet another object of this invention to provide such a therapeutic solution that is inexpensive to manufacture and administer while retaining its effectiveness. Further objects of the invention will be brought out in the following part of the specification, wherein detailed description is for the purpose of fully disclosing the invention without placing limitations thereon.
V. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT The present invention decreases the overall desire to smoke. Without being bound by any theory, the present inventor believes that the therapeutic solution when administered, produces a repugnant aftertaste to the user upon lighting and inhaling a cigarette or similar smoking device containing nicotine, due to the nicotine content of the cigarette chemically reacting with the ingredients of the therapeutic solution. Again, without being bound by any theory, the present inventor believes that the therapeutic solution comprising silver nitrate, glycerine, and demineralized water reacts with taste buds of the smoker to produce the repugnant aftertaste to the user lasting at least two to six hours. The Columbia Encyclopedia, Sixth Edition, 2001, defines silver nitrate as: a chemical compound, AgN03; a colorless crystalline material that is very soluble in water. The most important compound of silver, it is used in the preparation of silver salts for photography, in chemical analysis, in silver plating, in inks and hair dyes, and to silver mirrors. It is used in medicine in the treatment of eye infections and gonorrhea. Fused silver nitrate is also called lunar caustic. Taken internally silver nitrate is a poison. It is prepared by reaction of nitric acid with silver, and purified by recrystallization. It is darkened by sunlight or contact with organic matter such as the skin. The Columbia Encyclopedia, Sixth Edition, 2001, defines glycerine as: glycerin, glycerine, or 1,2,3-propanetriol, CH2OHCHOHCH2OH; colorless, odorless, sweet-tasting, syrupy liquid. Glycerol is a trihydric alcohol. It melts at 17.8°C, boils with decomposition at 290°C, and is miscible with water and ethanol. It is hygroscopic; i.e., it absorbs water from the air; this property makes it valuable as a moistener in cosmetics. Glycerol is present in the form of its esters (glycerides) in all animal and vegetable fats and oils. It is obtained commercially as a byproduct when fats and oils are hydrolyzed to yield fatty acids or their metal salts (soaps). Glycerol is also synthesized on a commercial scale from propylene (obtained by cracking petroleum), since supplies of natural glycerol are inadequate. Glycerol can also be obtained during the fermentation of sugars if sodium bisulfite is added with the yeast. Glycerol is widely used as a solvent; as a sweetener; in the manufacture of dynamite, cosmetics, liquid soaps, candy, liqueurs, inks, and lubricants; to keep fabrics pliable; as a component of antifreeze mixtures; as a source of nutrients for fermentation cultures in the production of antibiotics; and in medicine. It has many other uses as well. Again, without being bound by any theory, the present inventor believes that the repugnant aftertaste to the user produced from the reaction of the therapeutic solution with lighting and inhaling a cigarette or similar smoking device will reduce the desire and addiction of smoking for the user through continuous administration of the therapeutic solution. In the present invention for the cessation of smoking, the concentrated solution, the content seen in chart 1, is first diluted with a ratio of approximately 65% to 85% water and 35% to 15% concentrated solution. The diluted therapeutic solution is then administered with a dose of approximately 0.06 liter, up to six times a day, preferably orally, for a period of 30 days. The administration comprises the user rinsing and /or gargling up to three times with the 0.06 liter of diluted therapeutic solution and expelling it from the mouth of the user. During experimentation, smokers were administered the diluted therapeutic solution and all described a repugnant aftertaste to their taste buds lasting at least two to six hours upon lighting and inhaling a cigarette or similar smoking device containing nicotine. Another subject matter of the invention is a method of using a therapeutic water base solution to reduce the desire of a human being to smoke, comprising the steps of: A) diluting a concentrated solution comprising approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water to a ratio of approximately 65% to 85% water and 15% to 35% said concentrated solution; B) administering said therapeutic water base solution orally; C) rinsing and /or gargling said therapeutic water base solution with a dose of approximately 0.06 liter up to three times, up to six times a day, for a period of at least 30 days; and D) expelling said therapeutic water base solution. In an alternate embodiment, the therapeutic water base solution may be administered in aerosol form. Yet another subject matter of the invention is a method of preparing a concentrated solution, comprising the steps of: A) obtaining approximately between 170.00 cc and 230.00 cc of demineralized water; B) mixing approximately between 1.70 cc and 2.30 cc of silver nitrate into said demineralized water; and C) mixing approximately between 8.50 cc and 11.50 cc of glycerine into said demineralized water. The specification of an example concentrated solution prepared according to the described method is seen in chart 1 below. The contents listed are an average, and may fluctuate; cc is a metric unit of volume equal to one thousandth of a liter.
Figure imgf000010_0001
Chart 1
In the preferred embodiment, the concentrated solution is prepared according to the measurements seen in chart 1, however, silver nitrate may measure approximately between 1.70 cc and 2.30 cc; glycerine may measure approximately between 8.50 cc and 11.50 cc; and demineralized water may measure approximately between 170.00 cc and 230.00 cc.
The foregoing description conveys the best understanding of the objectives and advantages of the present invention. Different embodiments may be made of the inventive concept of this invention. It is to be understood that all matter disclosed herein is to be interpreted merely as illustrative, and not in a limiting sense. VI. INDUSTRIAL APPLICABILITY It is apparent from the previous paragraphs that a therapeutic water base solution for oral administration in humans comprising an effective amount of silver nitrate and glycerine to chemically react with nicotine to produce a repugnant aftertaste is quite desirable to reduce the desire of a human being to smoke. In addition, the therapeutic solution is inexpensive to manufacture and adrmnister while retaining its effectiveness.

Claims

VII. CLAIMS What is claimed is: 1. A therapeutic water base solution for oral administration in ' humans comprising an effective amount of silver nitrate and glycerine to chemically react with nicotine to produce a repugnant aftertaste.
2. The therapeutic water base solution set forth in claim 1, further characterized in that said therapeutic water base solution produces said repugnant aftertaste to said humans upon lighting and inhaling a cigarette or smoking device containing said nicotine, due to said nicotine content of said cigarette or smoking device chemically reacting with said therapeutic water base solution.
3. The therapeutic water base solution set forth in claim 2, further characterized in that said therapeutic water base solution reacts with taste buds of said humans to produce said repugnant aftertaste lasting at least two to six hours.
4. The therapeutic water base solution set forth in claim 3, further characterized in that said therapeutic water base solution comprises approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water in a concentrated form.
5. The therapeutic water base solution set forth in claim 4, further characterized in that said therapeutic water base solution is diluted to said effective amount, said effective amount comprising a ratio of approximately 65% to 85% water and 15% to 35% said concentrated form.
6. A method of using a therapeutic water base solution to reduce the desire of a human being to smoke, comprising the steps of: A) diluting a concentrated solution comprising approximately between 1.70 cc and 2.30 cc of silver nitrate, between 8.50 cc and 11.50 cc of glycerine, and between 170.00 cc and 230.00 cc of demineralized water to a ratio of approximately 65% to 85% water and 35% to 15% said concentrated solution; B) administering said therapeutic water base solution orally; C) rinsing and/ or gargling said therapeutic water base solution with a dose of approximately 0.06 liter up to three times, up to six times a day, for a period of at least 30 days; and D) expelling said therapeutic water base solution.
7. A method of preparing a concentrated solution, comprising the steps of: A) obtaining approximately between 170.00 cc and 230.00 cc of demineralized water; B) mixing approximately between 1.70 cc and 2.30 cc of silver nitrate into said demineralized water; and C) mixing approximately between 8.50 cc and 11.50 cc of glycerine into said demineralized water.
PCT/US2003/034971 2003-09-15 2003-11-03 Solution for cessation of smoking and method to use WO2005034968A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003286868A AU2003286868A1 (en) 2003-09-15 2003-11-03 Solution for cessation of smoking and method to use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66107703A 2003-09-15 2003-09-15
US10/661,077 2003-09-15

Publications (1)

Publication Number Publication Date
WO2005034968A1 true WO2005034968A1 (en) 2005-04-21

Family

ID=34435317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034971 WO2005034968A1 (en) 2003-09-15 2003-11-03 Solution for cessation of smoking and method to use

Country Status (2)

Country Link
AU (1) AU2003286868A1 (en)
WO (1) WO2005034968A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7900637B2 (en) 2001-06-25 2011-03-08 Niconovum Ab Device and method for the administration of a substance
US8741348B2 (en) 2002-12-20 2014-06-03 Niconovum Ab Physically and chemically stable nicotine-containing particulate material
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867181A (en) * 1986-03-18 1989-09-19 Smolko Milan S Non-smoking aid
US5122366A (en) * 1989-01-21 1992-06-16 The Arab Pharmaceutical Company Antismoke mouth wash comprising silver nitrate and propylene glycol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867181A (en) * 1986-03-18 1989-09-19 Smolko Milan S Non-smoking aid
US5122366A (en) * 1989-01-21 1992-06-16 The Arab Pharmaceutical Company Antismoke mouth wash comprising silver nitrate and propylene glycol

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7900637B2 (en) 2001-06-25 2011-03-08 Niconovum Ab Device and method for the administration of a substance
US8741348B2 (en) 2002-12-20 2014-06-03 Niconovum Ab Physically and chemically stable nicotine-containing particulate material
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US10219999B2 (en) 2006-03-16 2019-03-05 Niconovum Usa, Inc. Snuff composition
US11129792B2 (en) 2006-03-16 2021-09-28 Modoral Brands Inc. Snuff composition
US11547660B2 (en) 2006-03-16 2023-01-10 Niconovum Usa, Inc. Snuff composition

Also Published As

Publication number Publication date
AU2003286868A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
US10674762B2 (en) Aerosol generator
US6497859B1 (en) Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same
JP2017501714A (en) Liquid composition for electronic cigarette
US5810018A (en) Method, composition and apparatus for reducing the incidence of cigarette smoking
AU2011100027A4 (en) Nicotine containing soft gelatin pastilles
CA2914089C (en) Nicotine-containing liquid formulations and uses thereof
US4655231A (en) Snuff and preparation thereof
HUE025790T2 (en) Enhanced stability phenylephrine liquid compositions
JPS62500789A (en) Nasal composition containing vitamin B↓1↓2
BRPI0611258A2 (en) apomorphine pharmaceutical formulation for oral administration
EA025779B1 (en) Nicotine containing formulation
NO149312B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2- (2-TENOYLTIO) -PROPIONYLGYLINE
KR101257828B1 (en) Composition of antismoking aid containing damascone
WO2005034968A1 (en) Solution for cessation of smoking and method to use
DE2166355C2 (en) Use of d, 1-sobrerol in balm therapy of the respiratory tract
Fyfe Pocket Essentials of Modern Materia Medica and Therapeutics
CN106074305B (en) A kind of Noni fruit toothpaste and preparation method thereof with oral mucosa protective effect
US5032612A (en) Non-smoking aid
RU2745039C1 (en) Nicotine edible paper
AT414095B (en) Preparation useful e.g. to treat dry mucous membrane in oral and throat area comprises medical and/or food organic substance, flavor material, mucoadhesive substance, sugar (alcohol) and carrier substance e.g. fat and/or oil
RU2782018C1 (en) Remedy for those quitting smoking
CN105997539A (en) Anti-inflammatory and analgesic traditional Chinese medicinal toothpaste
CN110403891A (en) A kind of Chinese herbal toothpaste with oral health effect
JP4921662B2 (en) Aminoethanesulfonic acid-containing preparation
US20140271847A1 (en) Formulations and methods for rapid penile erections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OFF RIGHTS PURSUANT TO RULE 69(1)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP